Company intelligence / Profile preview

G.ST Antivirals

Vienna, Vienna, Austriagst-antivirals.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Reported positive Phase I clinical trial results in January 2024 for their nasal spray containing 2-Deoxy-D-glucose (2-DG), demonstrating safety and tolerability with no serious adverse events. Phase II clinical trial started on April 2, 2024.

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (2-Deoxy-D-glucose/2-DG)
Industry: Biotech

Drug pipeline

1 asset

2-deoxyglucose

Phase 2

Indications: Upper respiratory tract infections, Common cold

Beyond the preview

Go deeper on G.ST Antivirals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on G.ST Antivirals.

Explore the full profile